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Introduction {#sec1}
============

N-Methyl-D-aspartic acid receptors (NMDARs) are widely expressed in neurons and are composed of different subunits that form specific types of functional glutamate receptors. NMDARs are made up of an assortment of four subunits in a combination of two dimers ([@bib27], [@bib28]), where the *GRIN1* subunit is the only essential member and the most genetically distant from other members ([@bib12]). Subunit composition of NMDARs confers different biophysical properties on NMDARs such as glutamate binding affinities, activation/deactivation kinetics, or ion conductance ([@bib12]). Subunit expression patterns are often specific to developmental location or time window. For example, inclusion of *GRIN2* subunits A--D varies depending on brain region and developmental time window ([@bib22]), where *GRIN2B* is present in embryonic NMDARs but is replaced in postnatal NMDARs by *GRIN2A* ([@bib32]). The presence of *GRIN2C* likely occurs only in the cerebellum and after birth, and the presence *GRIN3A* and *GRIN3B* in NMDARs may influence synapse formation ([@bib13]). These consistent patterns of *GRIN1--3* expression suggest tight regulatory control and highlight the tuning of NMDARs to signal different effects in a cell.

The development of whole-genome sequencing technologies has allowed for major sequencing efforts of patients with neurodevelopmental disorders, and has underscored the importance of *GRIN2B* in human brain development. Large cohort studies for intellectual disability or autism spectrum disorders both have identified loss-of-function (LOF) mutations in *GRIN2B* that cause a severe neurological phenotype of broad spectrum ([@bib15], [@bib23]), a result supported by several case reports ([@bib14], [@bib17], [@bib18]). Homozygous *Grin2b*-deletion mice die at early postnatal stages due to impaired suckling response and show impaired hippocampal long-term depression ([@bib20]), while heterozygous mice show reduced expression of *GRIN2B* but survive. Human mutations in *GRIN2B* identified as likely pathogenic lead to LOF of one copy of the gene, a result consistent with a dominant genetic disorder due to either haploinsufficiency (reduced dosage \[RD\]) or production of a mutant gene product ([@bib18]), causing LOF. Fourteen percent (6/44) of human heterozygous *GRIN2B* mutation cases show gross cortical anomalies ([@bib24]) as measured by magnetic resonance imaging, while all mouse homozygous *Grin2b* mutants have grossly normal cerebral cortices. The large discrepancy in phenotype between human and mouse *GRIN2B* mutants suggests that the role of *GRIN2B* varies between the species.

While the role of *GRIN2B* in mature synapses, usually within hippocampal circuits, is intensely studied ([@bib8]), its role in neurodevelopment, particularly human brain development, is less well understood. GRIN2B-NMDARs (i.e., those NMDARs that have GRIN2B as a subunit) were initially hypothesized to be important in interpreting early signaling cues in the embryonic environment to guide neuronal differentiation ([@bib11]) before synapses form. This idea was supported by several studies from almost three decades ago that suggested that NMDARs may be an important part of neuronal differentiation in cortex, cerebellum, and spinal cord ([@bib4], [@bib7], [@bib10]). NMDA receptors are also critical for subventricular zone neural progenitor migration to the cortex in mouse ([@bib5]), an idea consistent with the importance of NMDA receptors in neural stem cells, an unambiguously non-synaptic developmental time point as cells can still become neurons, astrocytes, or oligodendrocytes. Given the reports of the importance of *GRIN2B* in cell differentiation, we reasoned that mutations in *GRIN2B* in human may lead to a neurodevelopmental disorder not only through its well-known role in synaptic plasticity but through a role in differentiating neural stem cells. To address this question without using animal models of brain development, we elected to use human induced pluripotent stem cells (iPSCs) to generate forebrain neurons.

Results {#sec2}
=======

Forebrain Neural Progenitor Cells Respond to NMDA and Express GRIN1 {#sec2.1}
-------------------------------------------------------------------

After extensive quality control including mycoplasma testing, endogenous marker staining, and molecular karyotyping in iPSCs ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}), we generated forebrain neural progenitor cells (NPCs) ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}). We define NPCs as committed forebrain progenitors that cycle indefinitely in basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) media and have the potential to become astrocytes, oligodendrocytes, or forebrain neurons. When these cells are differentiated for 30 days, \>90% of Tuj1-positive cells express glutamatergic (∼60%) or GABAergic (∼30%) markers, with a fraction (∼10%) expressing astrocytic makers ([Figures 1](#fig1){ref-type="fig"}D and 1E). As NPCs differentiate, the ratio of *GRIN2B*/*GRIN2A* rises, while cells matured for 30 days have an expression profile closest to mouse subventricular zone radial precursor cells at embryonic day 13.5 ([Figure S3](#mmc1){ref-type="supplementary-material"}). Differentiated forebrain NPCs form clusters as they mature into neurons and express synapsin-1 ([Figures 1](#fig1){ref-type="fig"}D and 1E). Differentiated cells are electrically active and demonstrate spontaneous action potentials ([Figures 1](#fig1){ref-type="fig"}H--1J).Figure 1Generation and Characterization of Forebrain Neurons(A) Outline of procedure used to generate iPSC-derived models of forebrain development.(B) Representative immunocytochemistry (ICC) for the four key pluripotency markers in control iPSCs. Scale bars represent 100 μm.(C) Representative ICC of control neural progenitor cells (NPCs) showing the absence of pluripotency markers and the presence of neuronal forebrain markers. Scale bars represent 50 μm.(D) Representative ICC of forebrain neuronal culture following 30 days of differentiation (D30) from NPCs, demonstrating the relative abundance of glutamatergic, GABAergic, and astrocytic markers in the population. Scale bars represent 50 μm.(E) Quantification of the percentage of cells positive for markers shown in (D). n = 8 images taken from separate coverslips from the same culture of D30 neurons. Error bars denote SD.(F) Representative ICC of forebrain neurons differentiated for 30 days from NPCs demonstrating uniform staining for the forebrain marker MAP2. Scale bar represents 50 μm.(G) Synapsin 1 (SYN1) staining in D30 neurons; Arrows highlight select SYN1 punctate, though many more are visible. Scale bar represents 50 μm.(H) Representative trace of resting membrane potential (RMP) observed in D18 neurons.(I) Representative trace of a hyperpolarizing pulses demonstrating that D18 neurons exhibit inward current and spontaneous action potential.(J) Representative trace of action potentials observed in D18 neurons during current ramp protocol.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Studies on subventricular zone NPCs isolated before cortical migration respond to NMDA and express subunits of NMDARs ([@bib5]). To assess human NPCs for the presence of functional NMDARs, we recorded from five independent NPCs ([Figures 2](#fig2){ref-type="fig"}A--2C), where two cells showed action potentials and one responded to NMDA, despite universal expression of NPC markers in these cultures ([Figure 2](#fig2){ref-type="fig"}D). The GRIN1 and GRIN2B protein was easily identifiable in NPCs via western blot, although expression in NPCs was lower than in these same cells matured for 30 days, as expected ([Figure 1](#fig1){ref-type="fig"}E). RNA sequencing of control NPCs (n = 3 cell lines) revealed expression of almost all NMDAR subunits as well as subunits from AMPA, kainate, and metabotropic glutamate receptors ([Figure S4](#mmc1){ref-type="supplementary-material"}). To unambiguously show NMDA response in NPC cultures, we have provided videos ([Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}) and images ([Figures 2](#fig2){ref-type="fig"}F and 2G) of calcium influx after application of NMDA in NPCs and D5 neurons, where D5 neurons show an increased response, likely reflecting a more mature stage of development. It is not immediately obvious whether some cells that are presumed to be in an NPC state are in fact differentiated. A further unknown is whether this is a function of *in vitro* techniques or may reflect NPC populations within the human brain.Figure 2Forebrain Neural Progenitor Cell Cultures Contain a Subpopulation of Cells that Are Electrically Active and Respond to NMDA(A) Morphology and electrophysiological characteristics of five healthy, control NPCs. Scale bars represent 10 μm.(B) Trace of RMP obtained from NPC 4.(C) Representative trace of a hyperpolarizing pulse applied to NPC 4 showing demonstrating inward current and spontaneous action potential.(D) NPC cells stain uniformly positive for forebrain NPC markers SOX1 and Nestin. Scale bar represents 50 μm.(E) Western blot showing relative level of expression of GRIN1 and GRIN2B in NPCs and D30 forebrain neurons.(F) Stills of NPCs and D5 neural cells incubated with the Fluo4 calcium indicator before and after application of NMDA. Stills obtained from [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}. Scale bars represent 40 μm.(G) Intensity of fluorescent signal detected in NPC and D5 neural cells following application of NMDA and vehicle (DMSO), as shown in [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}. Error bars denote SEM; n ≥ 46 cells from imaged wells.See also [Figure S4](#mmc1){ref-type="supplementary-material"}; [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Engineered Reduced Dosage and LOF Mutations in *GRIN2B* Impair Differentiation of NPCs {#sec2.2}
--------------------------------------------------------------------------------------

Using our simultaneous reprogramming and gene-editing protocol ([@bib6]), we generated clonal RD and LOF *GRIN2B* models. RD cells are heterozygous for a frameshift mutation in exon 11 and have one functional copy of *GRIN2B*, whereas LOF cells have two different *GRIN2B* mutant alleles, both with in-frame deletions of a large segment of the glutamate binding pocket ([Figures 3](#fig3){ref-type="fig"}A and 3B). RD has a ∼50% decrease in *GRIN2B* mRNA expression, whereas LOF has a milder decrease in mRNA expression of ∼25% ([Figure 3](#fig3){ref-type="fig"}C). Using independent replicates (control n = 4, LOF n = 4, RD n = 2), we differentiated NPCs for 30 days and performed whole transcriptomic sequencing in RNA extracted from these neurons, and found excellent segregation of expression patterns ([Figure 3](#fig3){ref-type="fig"}D). Both models of *GRIN2B* deficiency had several genome-wide significant gene-expression differences compared with the isogenic control cells, although we focused on those genes that showed expression differences in both *GRIN2B* mutant models, which revealed 657 differentially expressed genes common to both models (hypergeometric p \< 1.8 × 10^−204^) ([Figure 3](#fig3){ref-type="fig"}F). The strongest gene ontology terms for these common 657 genes were associated with genes related to increased cell proliferation and decreased cell differentiation ([Figure 3](#fig3){ref-type="fig"}G).Figure 3Genetically Engineered *GRIN2B*-Deficient Forebrain Neurons Show Impaired Differentiation(A) Location of gene-editing site within *GRIN2B*, Sanger sequencing of two edited lines, RD (reduced dosage) and LOF (loss of function). RD is heterozygous with only a single alteration resulting in a frame-shifted protein. LOF has two edited alleles, both of which are in-frame.(B) Structure of the NMDA receptor, with a magnified view of the glutamate binding site. The region of the glutamate binding site deleted in the LOF model is highlighted in pink.(C) RNA sequencing reads at the site of editing in transcripts obtained from control, RD, and LOF forebrain D30 neurons after 30 days of differentiation.(D) Hierarchical clustering of control, RD, and LOF D30 neurons after RNA sequencing. Heatmap of the commonly differentially expressed mRNAs in RD and LOF conditions compared with control.(E) Gene ontology terms related to significant enrichment of genes commonly deregulated in *GRIN2B* RD and in *GRIN2B* LOF differentiated neurons compared with controls. Corrected p values are expressed as −log.(F) Venn diagram showing the number of genes exclusively or commonly deregulated in *GRIN2B* LOF and in *GRIN2B* RD differentiated neurons.(G) Validation of *GRIN2B*, *KI67*, and *MET* mRNA differential expression in LOF and RD D30 neurons by qPCR. mRNA expression is normalized to *GAPDH* expression. Error bars denote SEM; n = 3 independent experiments, with each data point obtained from a separate culture of neuronal cells. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(H) Representative ICC images of GRIN2B, KI67, and MET immunopositive neurons in control, RD, and LOF conditions. Neurons were fixed at D30 of differentiation. Scale bars represent 50 μm.(I) Quantification of GRIN2B, KI67, and MET signals in control, RD, and LOF D30 neurons. The expression level expressed as normalized average signal is: (mean KI67 or MET pixel intensity) × (number of pixels above threshold/number of DAPI-positive pixels). Error bars denote SEM; n = 3 independent experiments, with each data point representing quantifications of coverslips obtained from separate cultures of each cell line. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(J) GRIN2B, KI67, and MET western blots of lysates from control, LOF, and RD forebrain neurons at D30.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Activation of NMDARs drives immediate-early gene expression ([@bib3]). Both *FOS* ([@bib33]) and *EGR1* ([@bib30]) are immediate-early genes that are downregulated in *GRIN2B* mutation models ([Figure S5](#mmc1){ref-type="supplementary-material"}A). *TBX3*, which itself is sufficient to maintain pluripotency of cells ([@bib25]), is upregulated in *GRIN2B* deficiency models ([Figure S5](#mmc1){ref-type="supplementary-material"}B). We observed decreases in *GRIN1* and *GRIN2A*, although *GRIN2A* was barely detectable ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5F).

We selected two significant and well-known markers, KI67 and MET, as output measures to assess the differentiation state of neurons and confirm RNA-sequencing data. Assessment of these markers in tandem with *GRIN2B* using qPCR, immunocytochemistry (ICC), and western blot ([Figures 3](#fig3){ref-type="fig"}G--3J), showed that while *GRIN2B* was consistently reduced in RD and LOF neurons compared with controls, KI67 and MET were consistently increased. This suggested that LOF and RD neurons were more immature than control neurons differentiated for the same amount of time.

A Missense Mutation in *GRIN2B* Impairs NPC Differentiation and Is Rescued by Genetic Repair {#sec2.3}
--------------------------------------------------------------------------------------------

We next generated neurons from a well-studied ([@bib2]) patient with autism and moderate intellectual disability. The subject has a heterozygous mutation (E413G) in the glutamate binding pocket of *GRIN2B* ([Figures 4](#fig4){ref-type="fig"}A and 4B), which is reported to decreases glutamate signaling \>50-fold ([@bib2]). Assessing the neurons in steps identical to those for the gene-edited *GRIN2B* models, we were able to fully recapitulate the deficient maturational state observed in RD and LOF neurons in patient neurons ([Figures 4](#fig4){ref-type="fig"}D--4G).Figure 4Forebrain Neurons Derived from a *GRIN2B* Mutation Patient Have Impaired Differentiation that Is Reversible by Genetic Repair(A) Structure of the NMDA receptor, with a magnified view of the glutamate binding site. The patient mutation E413G is displayed in pink and is highlighted with an orange arrow.(B) Sanger sequencing of the patient and a healthy control at the site of mutation in *GRIN2B*.(C) Average fold change of genes differentially expressed in iPSC-derived neurons from patient E413G compared with controls belonging to the Cell Cycle or Synapse GEO terms.(D) qPCR validation of *GRIN2B*, *KI67*, and *MET* mRNA upregulation in D30 neurons derived from the patient compared with control. Data normalized to *GAPDH* expression. Error bars denote SEM; n = 3 independent experiments, with each data point obtained from a separate culture of neuronal cells: ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(E) Representative ICC images of GRIN2B, KI67, and MET immunopositive neurons for patient and control D30 neurons. Scale bars represent 25 μm.(F) Quantification of GRIN2B, MET, and KI67 immunopositive signals in neurons from patient D30 neurons compared with control. Error bars denote SEM; n = 7 independent experiments, with each data point representing quantifications of coverslips obtained from separate cultures of each cell line. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(G) Western blot of GRIN2B, KI67, MET, and β-actin using lysates obtained from control and patient D30 forebrain neurons.(H) Western blot of C-FOS, P-CREB, CREB, and β-actin using lysates obtained from control and patient, RD, and LOF D30 forebrain neurons.(I) Diagram of the experimental procedure used to generate failed repair (RP-F) and successful repair (RP-S) neurons from patient fibroblasts.(J) Sanger sequencing of two failed and successful repaired lines at the site of mutation shown in (B).(K) Normalized expression level of *GRIN2B*, *MET*, and *KI67* mRNA in failed and successful repair D30 neurons. Measurements are matched by color to the specific line to which they correspond (blue: RP-F1; green: RP-F2; orange: RP-S1; red: RP-S2). Error bars denote SEM; n = 6 independent experiments, with each data point obtained from a separate culture of neuronal cells. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

A pathway whereby CREB becomes phosphorylated at serine 133 after NMDA stimulation and cell maturation has been identified ([@bib26]). To confirm deficiency in this pathway in patients and genetically engineered models of *GRIN2B* deficiency, we performed western blots to determine the protein levels of P133-CREB and CFOS, output markers of NMDA activation albeit non-specific ([@bib33]). The data strongly support the hypothesis that mutant *GRIN2B* impairs NMDA signaling ([Figure 4](#fig4){ref-type="fig"}H).

Patient cells can show altered levels of GRIN2B and other output measures due to genetic background. To address this, we corrected the patient mutation back to the wild-type sequence in two clonal lines ([Figures 4](#fig4){ref-type="fig"}I and 4J; [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Using clonal cell lines from the patient who failed to repair as control (n = 2), we differentiated all NPC lines for 30 days as assessed output makers GRIN2B, KI67, and MET via qPCR. We observed significantly higher expression of GRIN2B in repaired cells and lower levels of *KI67* and *MET* in failed repair patient cells ([Figure 4](#fig4){ref-type="fig"}K).

Pharmacological Block of NMDARs Impairs NPC Differentiation {#sec2.4}
-----------------------------------------------------------

Loss of *GRIN2B*, and presumably deficient NMDA signaling, increases MET and KI67 while decreasing *GRIN2B* expression. To determine whether pharmacological blockade of NMDARs or GRIN2B phenocopied these effects, we applied two concentrations of 2-amino-5-phosphonovalerate (APV), a competitive antagonist of NMDA, as well as ifenprodil, an uncompetitive inhibitor of NMDARs that contain GRIN2B ([@bib31]) for 30 days in culture ([Figure 5](#fig5){ref-type="fig"}A). We performed protein assessments of GRIN2B, KI67, and MET and found that both APV and ifenprodil produced a decrease in GRIN2B expression, but a significant increase in both KI67 and MET expression ([Figures 5](#fig5){ref-type="fig"}B--5D).Figure 5Pharmacological Block of NMDAR Impairs Neuronal Differentiation(A) Diagram showing the mechanism of action of APV and ifenprodil on NMDAR.(B) Representative ICC images of GRIN2B; MET, and KI67 immunostaining on D30 control neurons either untreated or treated with APV- or ifenprodil-supplemented medium every 72 hr. Scale bars represent 25 μm.(C) Quantification of GRIN2B, MET, and KI67 immunopositive signals shown in (B). Error bars denote SEM; n = 7 independent experiments, with each data point representing quantifications of coverslips obtained from separate cultures of each cell line. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(D) Western blot of GRIN2B, KI67, MET, and β-actin using lysates obtain from control D30 neurons differentiated in APV or ifenprodil-supplemented medium.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Mutations in *GRIN2B* Show Impaired Responses to NMDA {#sec2.5}
-----------------------------------------------------

To assess whether there is a functional consequence to both genetically engineered and the patient missense mutation in *GRIN2B*, we differentiated NPCs for 21 days and performed live calcium imaging and electrophysiological recordings. All three *GRIN2B*-deficient cell lines showed a reduced response to NMDA application compared with a control cell line ([Figures 6](#fig6){ref-type="fig"}A and 6B; [Video S3. Application of NMDA to D21 Control Neurons, Related to Figure 6](#mmc4){ref-type="supplementary-material"}, [Video S4. Application of NMDA to D21 Patient Neurons, Related to Figure 6](#mmc5){ref-type="supplementary-material"}, [Video S5. Application of NMDA to D21 RD Neurons, Related to Figure 6](#mmc6){ref-type="supplementary-material"}, [Video S6. Application of NMDA to D21 LOF Neurons, Related to Figure 6](#mmc7){ref-type="supplementary-material"}). Electrophysiological recordings also presented decreased frequency and amplitude of responses after application of NMDA compared with control cells ([Figures 6](#fig6){ref-type="fig"}C and 6D).Figure 6Forebrain Neurons with Genetic Deficiency in *GRIN2B* Show Impaired Responses to NMDA(A) Stills of D21 control, patient, RD, and LOF forebrain neurons incubated with the Fluo4 calcium indicator before and after application of NMDA. Stills obtained from [Video S3. Application of NMDA to D21 Control Neurons, Related to Figure 6](#mmc4){ref-type="supplementary-material"}, [Video S4. Application of NMDA to D21 Patient Neurons, Related to Figure 6](#mmc5){ref-type="supplementary-material"}, [Video S5. Application of NMDA to D21 RD Neurons, Related to Figure 6](#mmc6){ref-type="supplementary-material"}, [Video S6. Application of NMDA to D21 LOF Neurons, Related to Figure 6](#mmc7){ref-type="supplementary-material"}. Scale bars represent 40 μm.(B) Intensity of fluorescent signal detected in D21 control, patient, RD, and LOF forebrain neurons following application of NMDA and vehicle, as shown in [Video S3. Application of NMDA to D21 Control Neurons, Related to Figure 6](#mmc4){ref-type="supplementary-material"}, [Video S4. Application of NMDA to D21 Patient Neurons, Related to Figure 6](#mmc5){ref-type="supplementary-material"}, [Video S5. Application of NMDA to D21 RD Neurons, Related to Figure 6](#mmc6){ref-type="supplementary-material"}, [Video S6. Application of NMDA to D21 LOF Neurons, Related to Figure 6](#mmc7){ref-type="supplementary-material"}. Error bars denote SEM; n ≥ 58 cells imaged from a well containing each cell line.(C) Frequency of excitatory postsynaptic currents (EPSCs) in control, patient, RD, and LOF neurons after application of vehicle and 2 μM NMDA. Neurons measured between D5 and D9 differentiation time point.(D) Amplitude histogram distribution of EPSCs after application of vehicle or NMDA as described in (C). Amplitude distribution was fitted using a Gaussian fit.(E) Frequency of EPSCs after application of vehicle or 2 μM NMDA as described in (C).See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Video S3. Application of NMDA to D21 Control Neurons, Related to Figure 6](#mmc4){ref-type="supplementary-material"}, [Video S4. Application of NMDA to D21 Patient Neurons, Related to Figure 6](#mmc5){ref-type="supplementary-material"}, [Video S5. Application of NMDA to D21 RD Neurons, Related to Figure 6](#mmc6){ref-type="supplementary-material"}, [Video S6. Application of NMDA to D21 LOF Neurons, Related to Figure 6](#mmc7){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

This work provides a description of iPSC-derived models of *GRIN2B* mutations. All models point to a significant role of *GRIN2B* and NMDARs in cell differentiation, consistent with previous reports showing that stimulation of NMDA receptors affects neuron development ([@bib1], [@bib7], [@bib29]). We propose a model whereby GRIN2B-NMDA receptors are critical for signal transduction in neural stem cells. Deficits in this process delay or impair differentiation, including *GRIN2B* expression itself, further impairing differentiation. This suggests a feedforward loop whereby NMDA signaling leads to more expression of *GRIN2B*, and thus more NMDA signaling. We hypothesize that this feedforward loop is not specific to *GRIN2B*, but rather the general differentiation state of the cell. Glutamate signaling through NMDA in neural stem cells or immediately postmitotic neurons may be critical for cells to interpret their environment and differentiate accordingly. In our study we could detect NMDA response in some NPCs as well as action potential generation. There are two possible explanations for this. (1) Cells that stain positive for PAX6, NESTIN, and SOX2 are not truly NPCs but rather cells that have differentiated. On close inspection ([Figure 2](#fig2){ref-type="fig"}, NPC \#4) some NPCs show bipolar morphology, which has implications for these markers in these types of studies. It also has implications for the probabilistic nature of proliferation and differentiation itself, specifically that NPCs may constantly want to differentiate but are held in a proliferative state by the presence of growth factors, with a small minority of cells differentiating regardless under these conditions *in vitro*. (2) Alternatively, NPCs have functional NMDARs that contain *GRIN2B*, in which case the definition of NMDAR function needs to be expanded beyond its role in the synapse and synapse assembly, as has been suggested in mouse ([@bib5]). We favor the latter explanation without discounting the former, but neither may be mutually exclusive.

These data are consistent with a model of neurodevelopmental disease whereby any genetic alteration that alters the precise timing of neuronal differentiation may lead to altered numbers of progenitor cell populations and/or integration of cells into developing circuits ([@bib16]). In the current work, loss of *GRIN2B* function may retain cells in a more proliferative-like state, impairing differentiation and, presumably, how neurons integrate into developing circuits. In our view, this is the link between the divergent and extensive list of genes that when mutated lead to variable phenotypes related to intellectual disability. For example, mutations in *PTEN*, *CHD8*, or *CDKL5* all lead to neurodevelopmental disease, and all have a role in cell proliferation.

There have been intensive studies of the role of genes expressed at synapses in neurodevelopmental diseases ([@bib9]), and we suggest that *GRIN2B* action in neural stem cells may also play a role in these diseases. This leads to a larger question: might other genes with strong associations with neurodevelopment and usually considered in a synaptic context (e.g., *NRXN1* \[[@bib19]\] or *SHANK3* \[[@bib21]\]) also have a role in early cell differentiation? Our study suggests that perhaps other genes considered to have a primarily synaptic function might play a key role in developing neurons.

Experimental Procedures {#sec4}
=======================

Somatic Cell Reprogramming {#sec4.1}
--------------------------

The induction of iPSCs and their subsequent differentiation into neuronal cells was carried out using methods identical to those described previously ([@bib6]). All cell lines were generated from fibroblasts. Control fibroblasts were obtained from the Coriell Cell Repository (Camden, USA), and patient fibroblasts were obtained from the Ann & Robert H. Lurie Children\'s Hospital of Chicago (Chicago, USA) in adherence with ethical research principles and under protocols approved by the local institutional review board. Further information regarding the cell lines used in this experiment can be found in [Table S1](#mmc1){ref-type="supplementary-material"}.

Fibroblasts were reprogrammed using episomal reprogramming vectors containing Oct4, Sox2, Myc3/4, Klf4, and ShRNA P53 (ALSTEM) and a Neon Transfection System (Invitrogen, Burlington). A total of 5.0 × 10^5^ cells were electroporated and reprogrammed with 5 μg of episomal vectors per reaction. Electroporation parameters were as follows: 11,650 V, 10 ms, 3 pulses. Following transfection, cells were plated at extremely low density (∼10 cells per well) on tissue culture plates coated with Matrigel (Corning) in 10% fetal bovine serum (FBS) DMEM. The following day, the medium was exchanged for fresh 10% FBS DMEM supplemented with 2 μg/mL puromycin, where applicable (Sigma-Aldrich). Puromycin selection was applied for 48 hr, after which the medium was exchanged with fresh TesR-E7 medium (STEMCELL Technologies, Vancouver). During the induction process, TesR-E7, medium was changed every day. Single iPSC colonies were observed, and could be seen forming from a single skin cell. Once colonies formed a distinct border (∼500--1,000 μm in diameter), cells were detached using ReLeSR medium (STEMCELL), and replated in mTesR1 medium (STEMCELL) supplemented with ROCK inhibitor y-27632 (Sigma-Aldrich) at a final concentration of 10 μM.

Quality Control of iPSCs {#sec4.2}
------------------------

iPSCs were rigorously characterized using several assays. All cells underwent short tandem repeat profiling using ten markers to ensure that derived cells could always be related back to their source cell. All cells were tested for mycoplasma contamination (EZ-PCR Mycoplasma Test Kit \[Biological Industries\]). Pluripotency was assessed by immunostaining with surface and nuclear pluripotency markers ([Figure S1](#mmc1){ref-type="supplementary-material"}), and spontaneous 7-day embryoid body (EB) differentiation confirmed the capacity to form the three germ layers. Once iPSC lines were stable, we performed array comparative hybridization (aCGH; Cytoscan HD at SickKids Toronto; Thermo Fisher Scientific). No *de novo* CNVs \>1 Mb were observed in any colonies, and no *de novo* rare CNVs (\<1% in Caucasian population) were observed in genes.

Genetic Engineering {#sec4.3}
-------------------

CRISPR gene editing was performed concurrently with iPSC induction, using previously published protocols ([@bib6]). More information regarding CRIPSR design, including the regions of *GRIN2B* targeted, guide RNA sequences, and sequencing chromatograms can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

iPSC Differentiation to Forebrain Progenitor Cells {#sec4.4}
--------------------------------------------------

iPSCs were dissociated using Gentle Cell Dissociation Reagent (STEMCELL) and resuspended in Neural Induction medium (DMEM/F12 supplemented with N2 \[Invitrogen\], B27 supplement \[Invitrogen\], BSA \[1 mg/mL\], Y27632 \[10 μM; AdooQ Bioscience\], SB431542 \[10 mM; Selleckchem\], and noggin \[200 ng/mL; GenScript\]), onto low-bind plates (Corning) or Petri dishes (Corning). Cells were plated at a density of 2--3 × 10^6^ cells per 100-mm^2^ plate. Cells were cultured in suspension and monitored for the formation of organoids, which occurred approximately 4 days after suspension. Three days after the formation of EBs, a 70-μm Falcon cell strainer was used to collect aggregations, which were then resuspended in a fresh low-bind/Petri dish in Neural Progenitor (NP) medium (DMEM/F12 supplemented with N2, B27 supplement, bFGF \[20 ng/mL; GenScript\], EGF \[20 ng/mL; GenScript\], laminin \[1 μg/mL; Sigma-Aldrich\]). The medium was exchanged every day for fresh NP medium for 14 days. Following 14 days in NP medium, cell aggregations were resuspended in Final Differentiation (FD) medium (DMEM/F12 supplemented with N2, B27 supplement, brain-derived neurotrophic factor \[20 ng/mL; GenScript\], glia-derived neurotrophic factor \[20 ng/mL; GenScript\], laminin \[1 μg/mL\]). FD medium was changed every 2 days for 7 days. Organoids were plated on polyornithine- and laminin-coated tissue culture plates in Neuron Maturation (NM) medium (DMEM/F12 supplemented with N2, B27 supplement). Following attachment, organoids were dissociated with 0.05% trypsin-EDTA and replated onto fresh polyornithine- and laminin-coated plates in NM medium. Half the medium was exchanged for fresh medium every 3 days.

Videomicroscopy {#sec4.5}
---------------

Cells were seeded in 35-mm MatTek Dishes (MatTek) in the StemDiff Neural Progenitor Medium and differentiated for up to 21 days At the day of the acquisition, the Fluo4 calcium indicator (Thermo Fisher) was incubated for 30 min at a final concentration of 1 μM. Cells were then washed twice for 5 min with the differentiation medium before acquisition. Acquisition were performed using an Axio Observer Z1 microscope (Zeiss) assisted by Zen 2 software. Pictures were collected at every 400 ms for 5 min, with a correction for defined focus every 30 pictures. At picture 120 a vehicle solution was applied, corresponding to cell-culture medium in the case of subsequent NMDA. At picture 240, NMDA was applied at a final concentration of 2 μM. The acquisitions were treated using Fiji/ImageJ software. Threshold was set up to perform a segmentation of the cells, and ROIs were determined and collected through the particle analysis module. Multiple measurement tool from the ROI manager was used to the measure the mean pixel values of each ROI in each picture of the time stack. For the acquisition performed at the NPC stage, a manual segmentation was required to analyze Fluo4 fluorescence variations upon NMDA application. The rest of the data collection process remained the same. Once the data were extracted from the time stack, background was subtracted from every single ROI at every time point. Signal variation is expressed as ΔF/F~0~, F~0~ being the minimal intensity signal for a given ROI after background subtraction and ΔF being the difference between an intensity signal at a given time point and F0. Amplitude of ΔF/F~0~ variations following NMDA applications were monitored in the ROIs and averaged to compare responses between the different conditions. The time stacks were submitted to a JPEG compression at 20 fps to obtain videos.

Electrophysiology {#sec4.6}
-----------------

For whole-cell patch-clamp recordings, individual coverslips containing differentiated human iPSC-derived neurons were transferred into a heated recording chamber and continuously perfused (1 mL/min) with BrainPhys Neuronal Medium (STEMCELL) bubbled with a mixture of CO~2~ (5%) and O~2~ (95%) and maintained at 35°C. Whole-cell patch-clamp recordings were obtained using borosilicate pipettes (3--6 MΩ) filled with intracellular solution that contained the following: 5 in mM HEPES, 2 in mM KCl, 136 in mM potassium gluconate, 5 in mM EGTA, 5 in mM Mg-ATP, 8 in mM creatine phosphate, and 0.35 in mM guanosine triphosphate. The pH was adjusted to 7.27 with KOH, and the osmolarity adjusted with distilled water or concentrated potassium gluconate if needed to between 295 and 298 mOsm with an osmometer (Advanced Instruments). After a recording was completed, we corrected the nominal membrane potential in voltage- and current-clamp recordings for the calculated 10-mV liquid junction potential. All potential values reported reflect this correction. Once whole-cell recording had been established, neurons were routinely held in voltage clamp at −70 mV except when examining changes in the resting membrane potential and rheobase, which was performed in current clamp. Cells were only studied if they exhibited a stable holding current and access resistance for at least 10 min before experimental manipulations. Data were acquired using a Digidata 1550A/Multiclamp 700B (Axon Instruments) and Clampex 10.5 (Molecular Devices). Currents were filtered at 2 kHz and digitized at 20 kHz.

qPCR {#sec4.7}
----

Reverse transcriptions were done on the total RNA fraction in order to obtain cDNA in 40-μL volume containing 1 μg of total RNA, 0.5 μg of random primers, 0.5 mM dNTPs, 0.01 M DTT, and 400 U M-MLV RT (Invitrogen). The reactions were performed in a total volume of 20 μL on a 384-well plate using either an Applied Biosystems 7900 HT (Applied Biosystems) or a QuantStudio 6 (Thermo Fisher) PCR machine. For each well, PCR mix included 10 μL of 2× No AmpErase UNG master mix (Applied Biosystems) for Taqman assays or 10 μL of Power SybrGreen PCR Mastermix (Life Technologies), 1 μL of primers/probe mix, 2 μL of cDNA, with H~2~O up to 20 μL. Serial dilutions of a mix of cDNA ranging between 0.003052 ng and 50 ng were used to generate a calibration curve for an absolute quantification. Expression levels were given as a ratio between the relative quantities of the gene of interest and the endogenous control. GAPDH was used as internal control for normalization. The normalized expression levels were then compared between cell lines using ANOVA with a post hoc t test. Further details on the primers used for qPCR can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunocytochemistry and Microscopy {#sec4.8}
----------------------------------

Cells were plated on glass coverslips coated with Matrigel. Once cells were ready for ICC they were washed with PBS and fixed with 3% paraformaldehyde (Sigma-Aldrich) for 15 min. Samples were permeabilized with 0.5% TX-100 (Sigma-Aldrich) in 0.5% PBS-BSA for 15 min and then blocked in 0.5% PBS-BSA for an additional 15 min. Primary antibodies were added in appropriate dilutions in 0.5% PBS-BSA and added to samples for 30 min. Samples were washed, then 0.5% PBS-BSA containing an appropriate dilution of secondary antibody was added to the samples and incubated for 30 min in the dark. Samples were washed with 0.5% PBS-BSA and visualized on an FV1200 laser scanning microscope (Olympus). Further details on the antibodies used for ICC can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Data Acquisition from Images {#sec4.9}
----------------------------

All ICC images were analyzed using the software ImageJ. Images were converted to an 8-bit mode allowing pixel values in a range between 0 and 256. A threshold was set for each channel to discriminate specific signal intensities from the background. The threshold was determined on the condition presenting the highest signal-to-noise ratio. The average pixel intensities above threshold were normalized by the number of DAPI-positive pixels to minimize biases generated by differences in cell number in between acquisition fields. Data between groups were compared using t tests that followed ANOVA when required. Statistical analyses were performed using SPSS 20.

Western Blotting {#sec4.10}
----------------

Cells were lysed with RIPA buffer (Sigma) supplemented with SIGMAFAST Protease Inhibitor Tablets (Millipore-Sigma). Protein concentrations were determined using a Pierce BCA Protein Assay Kit (Thermo Fisher). Approximately 15 μg of protein was loaded per well in Mini-PROTEAN TGX Stain-Free Precast Gels (Bio-Rad). Gels were run at 150 V for approximately 75 min and then transferred to a nitrocellulose membrane using a Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked in 4% non-fat milk dissolved in Tris-buffered saline plus Tween 20 (TBST) buffer (Sigma-Aldrich) for 20 min, then incubated with primary antibodies overnight at 4°C with shaking. Blots were washed three times in TBST for 5 min and then incubated with appropriate mouse or rabbit secondary antibodies for 1 hr at room temperature. Blots were washed a further three times in TBST for 5 min, then imaged using a ChemiDoc XRS+ System (Bio-Rad). Blots were imaged and analyzed using ImageLab software, and statistical analysis was performed using Student's t tests when two sample conditions were present and one-way ANOVA when more than two sample conditions were present. Further details on the antibodies used can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Pharmacological Blockade {#sec4.11}
------------------------

NPCs were plated on glass coverslips coated with Matrigel, and differentiated in medium supplemented with 10 μM and 50 μM of APV (Tocis) or 3 μM of ifenprodil (Tocris) for 30 days. All other cell-culture parameters were identical to the differentiation protocol cited above. Every 3 days, half of the medium was exchanged. After 30 days the coverslips were removed and prepared for ICC as described above.

Additional Methods {#sec4.12}
------------------

Sanger sequencing, RNA extraction and sequencing, comparison of transcriptomics profiles, and GEO analysis can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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